Logo of OrganaBio

OrganaBio

OrganaBio, LLC is a vertically integrated cell therapy contract development and manufacturing organization (CTDMO) headquartered in Miami, Florida, with cGMP manufacturing and cell processing facilities in Miami and San Diego and regional cell processing labs in San Francisco and Irvine. Through its wholly owned, FDA-registered subsidiaries – HemaCenter, LLC (adult leukapheresis) and GaiaGift, LLC (birth tissue and cord blood) – OrganaBio operates proprietary supply chains for ethically sourced human tissues and blood-derived cellular products. The combined platform delivers GMP isolated cells, clinical-sample processing including PBMC isolation, cell isolation and cryopreservation services, cGMP manufacturing for autologous and allogeneic cell therapies, process development, analytical testing, quality assurance, and regulatory support under a single quality framework, enabling cell therapy developers to accelerate the path from development to patient. For more information, visit www.organabio.com.

Content by OrganaBio

Abstract illustration of cells.
| 2 min read
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.